Cancer

Verzenios is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor developed by Lilly for the treatment of several forms of breast cancer.

Unlike CAR-T therapy, which requires patient-specific cell modification and lengthy manufacturing, this treatment is delivered as a ready-to-use infusion, making it more accessible in standard hospital settings.

The decision makes satri-cel the first CAR-T therapy anywhere in the world to receive regulatory approval for a solid tumor indication.

The deal integrates Firefly Bio’s experimental Firelink degrader-antibody conjugate platform into J&J’s oncology research and development portfolio, marking a significant step in its long-term strategy to enhance targeted drug delivery systems.

Established in 2022, the collaboration combines CytomX’s Probody masking technology with Regeneron’s Veloci-Bi bispecific antibody platform.

Phesgo, manufactured by Roche, contains a combination of Pertuzumab and Trastuzumab and is used in the treatment of specific types of breast cancer.

The Noguchi Institute’s newly licensed technology focuses on controlling two critical aspects of ADC design: the drug-to-antibody ratio (DAR) and the precise attachment site of the therapeutic payload.

NICE recommended Imfinzi for adults whose stomach cancer has not spread extensively and can be removed through surgery, including gastric and gastro-oesophageal junction cancers that physicians frequently diagnose at advanced stages.

The procedure, known as intraoperative pathological assessment using imprint cytology, enables pathologists to identify cancer cells within minutes.

If fully developed and commercialized, Huahui Health could receive up to US$1.9 billion in milestone-based payments, in addition to tiered royalties on future global sales.